Mineralys Therapeutics Inc
MLYS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.26B
Close$
$2.56
91.2% downside
Current Fair Value
91.2% downsideOvervalued by 91.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.26 Billion |
|---|---|
| Enterprise Value | $2.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.29 |
| Beta | 0.68 |
| Outstanding Shares | 84,727,282 |
Return
| Return on Equity | -63.45% |
|---|---|
| Return on Assets | -52.34% |
| Return on Invested Capital | -55.76% |
Valuation & Multiples
| P/E Ratio | -6.04 |
|---|---|
| PEG | -1.32 |
| Price to Sales | - |
| Price to Book Ratio | 4.84 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.13 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7500▼ 29.90% |
|---|---|
| Total Calls | 1,573,000▼ 56.09% |
| Total Puts | 1,179,800▼ 68.60% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 123.07%▼ 10.43% |
|---|---|
| Total Invested | $2.77B▲ 12.79% |
| Investors Holding | 241▲ 12.00% |
ESG Score
No data